Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SKP2 | Q13309 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414579 | 0.88 | TDP1 (0.50) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL3634662 | 0.86 | TDP1 (0.48) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| SCHEMBL11745408 | 0.84 | SKP2 (0.47) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| SCHEMBL19526504 | 0.82 | ALOX15 (0.45) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| SCHEMBL30227228 | 0.82 | SKP2 (0.48) | SKP2TDP1ALOX15TP53CYP3A4 | |
| SCHEMBL39005 | 0.82 | SKP2 (0.48) | SKP2TDP1ALOX15TP53CYP3A4 | |
| SCHEMBL5377476 | 0.82 | SKP2 (0.48) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| SCHEMBL28094009 | 0.81 | TYR (0.48) | SKP2TDP1ALOX15TP53SMN1; SMN2 | |
| SCHEMBL5382666 | 0.81 | NR4A1 (0.47) | SKP2SMN1; SMN2TLR8ALDH1A1NPC1 | |
| SCHEMBL8375841 | 0.80 | SKP2 (0.67) | SKP2SMN1; SMN2TLR8ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022129349-A1 | DYEING COMPOSITION BASED ON 2-GAMMA-HYDROXYPROPYL-PARA-PHENYLENEDIAMINE AND A PHOSPHORIC SURFACTANT | L'OREAL (FR) | 2022-06-23 | — | — | WO | disclosed |
| US-9469654-B2 | Bicyclic oxa-lactam kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150340519-A1 | HIGHLY-FLUORESCENT AND PHOTO-STABLE CHROMOPHORES FOR WAVELENGTH CONVERSION | NITTO DENKO CORPORATION (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | ALEXION PHARMACEUTICALS, INC. | 2015-09-10 | — | — | US | disclosed |
| US-9040530-B2 | 1,2,4-triazine-6-carboxamide kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-8231792-B2 | Purification of ionic liquids | BASF AKTIENGESELLSCHAFT (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20090250409-A1 | PURIFICATION OF IONIC LIQUIDS | BASF AKTIENGESELLSCHSFT (DE) | 2009-10-08 | — | — | US | disclosed |
| EP-1824575-A1 | PURIFICATION OF IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006061188-A1 | PURIFICATION OF IONIC LIQUIDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-15 | — | — | WO | disclosed |
| US-4079012-A | Synthetic ester oil compositions containing organic sulfonic acid ammonium salts as load-carrying agents | BOSNIACK DAVID S | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252056-A1 | BICYCLIC OXA-LACTAM KINASE INHIBITORS | SYK, BTK, JAK2 | SKP2 172/4885TDP1 2178/4885ALOX15 1564/4885 |
| US-20140113931-A1 | SUBSTITUTED PICOLINAMIDE KINASE INHIBITORS | SYK, LCK, BTK | SKP2 183/4885TDP1 986/4885ALOX15 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.